Literature DB >> 32322680

Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects.

José Alexandre S Crippa1,2, Antonio Waldo Zuardi1,2, Jaime Eduardo Cecílio Hallak1,2, Bruna Miyazawa3, Sandra Aparecido Bernardo1,2, Carmem Maria Donaduzzi4, Silvane Guzzi5, Wagner Alex Jann Favreto5, Alline Campos1,6, Maria Eugênia C Queiroz1,7, Francisco S Guimarães1,6, Patrícia Moura da Rosa Zimmermann4, Letícia Mello Rechia4, Volnei Jose Tondo Filho4, Liberato Brum Junior4.   

Abstract

Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and
Methods: Thus, we tested the plasma samples of 120 healthy human subjects (60 male and 60 female), 60 in fasting and the other 60 under normal feeding conditions after acute administration of an oral solution containing CBD 300 mg. To do this, we developed a bioanalytical method to determine CBD and the presence of THC in plasma samples by Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
Results: The results showed that THC was not detected in plasma after the administration of CBD, and those study participants did not present psychotomimetic effects. Conclusions: The findings presented here are consistent with previous evidence suggesting that the oral administration of CBD in a corn oil formulation is a safe route for the administration of the active substance without bioconversion to THC in humans. Copyright 2020, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  UHPLC-ESI-MS/MS; cannabidiol; delta-8-tetrahydrocannabinol; delta-9-tetrahydrocannabinol; interconversion; pharmacokinetics; protein precipitation

Year:  2020        PMID: 32322680      PMCID: PMC7173681          DOI: 10.1089/can.2019.0024

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  22 in total

1.  Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.

Authors:  Federica Palazzoli; Cinzia Citti; Manuela Licata; Antonietta Vilella; Letizia Manca; Michele Zoli; Maria Angela Vandelli; Flavio Forni; Giuseppe Cannazza
Journal:  J Pharm Biomed Anal       Date:  2017-11-28       Impact factor: 3.935

2.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Authors:  Orrin Devinsky; J Helen Cross; Linda Laux; Eric Marsh; Ian Miller; Rima Nabbout; Ingrid E Scheffer; Elizabeth A Thiele; Stephen Wright
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

Review 3.  Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

Authors:  Alexandre R de Mello Schier; Natalia P de Oliveira Ribeiro; Danielle S Coutinho; Sergio Machado; Oscar Arias-Carrión; Jose A Crippa; Antonio W Zuardi; Antonio E Nardi; Adriana C Silva
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

4.  Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Authors:  John Merrick; Brian Lane; Terri Sebree; Tony Yaksh; Carol O'Neill; Stan L Banks
Journal:  Cannabis Cannabinoid Res       Date:  2016-04-01

5.  Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Authors:  Orrin Devinsky; Anup D Patel; J Helen Cross; Vicente Villanueva; Elaine C Wirrell; Michael Privitera; Sam M Greenwood; Claire Roberts; Daniel Checketts; Kevan E VanLandingham; Sameer M Zuberi
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

6.  Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.

Authors:  M H N Chagas; A L Eckeli; A W Zuardi; M A Pena-Pereira; M A Sobreira-Neto; E T Sobreira; M R Camilo; M M Bergamaschi; C H Schenck; J E C Hallak; V Tumas; J A S Crippa
Journal:  J Clin Pharm Ther       Date:  2014-05-21       Impact factor: 2.512

7.  Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.

Authors:  Ila M Linares; Antonio W Zuardi; Luis C Pereira; Regina H Queiroz; Raphael Mechoulam; Francisco S Guimarães; José A Crippa
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

Review 8.  A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Authors:  Antonio Waldo Zuardi; Jose Alexandre S Crippa; Jaime E C Hallak; Sagnik Bhattacharyya; Zerrin Atakan; Rocio Martin-Santos; Philip K McGuire; Francisco Silveira Guimarães
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.

Authors:  Gerhard Nahler; Franjo Grotenhermen; Antonio Waldo Zuardi; José A S Crippa
Journal:  Cannabis Cannabinoid Res       Date:  2017-05-01

10.  Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036.

Authors:  Marcel O Bonn-Miller; Stan L Banks; Terri Sebree
Journal:  Cannabis Cannabinoid Res       Date:  2017-01-01
View more
  2 in total

1.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

2.  Letter to the Editor: The Controversial Cannabidiol Cyclization: Its Conceptual Origin.

Authors:  Crist N Filer
Journal:  Cannabis Cannabinoid Res       Date:  2020-10-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.